4 terminated. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Deaf-Blind Disorders: new trials by email Literature Review of Deaf-Blind Disorders trials Research Report on Deaf-Blind Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
Retinitis Pigmentosa (4) · Usher Syndromes (4) · Eye Diseases (3) · Retinal Diseases (3) · Vision Disorders (3) · Eye Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (1) · Night Blindness (1)
Abnormalities, Multiple (4) · Blindness (4) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Deafness (4) · Ear Diseases (4) · Hearing Disorders (4) · Hearing Loss (4) · Hearing Loss, Sensorineural (4) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Otorhinolaryngologic Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Retinal Degeneration (4)
Laboratoires Thea (3) · Sanofi (1)
United States (4) · France (2) · United Kingdom (2) · Canada (1) · Germany (1) · Netherlands (1)
Jose-Alain Sahel, MD, PhD (1) · Richard Weleber, MD (1)